The median survival time for the low-EPC1 expression group was 33.10 months, and the median survival time for the high-EPC1 expression group was 61.27 months; the difference was statistically significant (HR < 1, P < 0.01), suggesting that HNSCC patients with high EPC1 expression have a better prognosis. The gene discussed is EPC1; the disease is head and neck squamous cell carcinoma.